Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have a diagnosis of mild to moderate Alzheimer's dementia (stage 4 or 5).
- You have a reliable caregiver or study partner who can spend at least 10 hours per week with you and attend all visits.
- You have had a biomarker test (amyloid PET, spinal tap, or blood test) within the last 3 years that confirms Alzheimer's.
- You are currently taking a stable dose of donepezil, rivastigmine, or galantamine for at least 3 months.
- You have not previously received an anti-amyloid medication (like Aduhelm, Leqembi, or donanemab) or an Alzheimer's vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.